Stat says the Biden administration announcement, made today, is merely the "latest salvo" in a protracted battle over insurers' plans that skimp on treating a number of mental health issues. Also in ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short selling ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

That candidate hits the same target as Elahere, the ADC that AbbVie acquired in its $10 billion takeover of ImmunoGen. Elahere received full FDA approval in ovarian cancer this year, but ...

But that doesn't mean they'll be spared election noise. AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and strategic ...

AbbVie is in the midst of an extended move up the charts that has taken shares to new highs. As it now approaches $200, there is reason to believe that the company's share price may soon need to ...